New on NCI’s Websites for May 2017

May 30, 2017, by NCI Staff

NCI’s cancer information products are constantly growing, so periodically we provide updates on new and updated content of interest to the cancer community.

Annual Report to the Nation

The 2017 Annual Report to the Nation, published in the Journal of the National Cancer Institute, provides an update on cancer incidence (new cases) and mortality (death) rates, and trends in these rates in the United States. It also includes a special section on survival.

New Cancer Statistics Review Released

The newest edition of SEER Cancer Statistics Review has been released by NCI’s Surveillance, Epidemiology, and End Results (SEER) program. The latest edition includes statistics for 1975 through 2014, the most recent year for which data are available.

New Did You Know? Series Videos

The latest video in NCI’s Did You Know? series talks about oral cavity and pharynx cancers. These cancers are most common in white men. Oropharynx cancers are strongly linked to infection with the human papillomavirus (HPV).

Also, a new video about ovarian cancer was added to the series in March. The video addresses the different types of ovarian cancer, survival and other statistics, which population groups are most at risk, and common risk factors.

Screen to Save Connect Webpage

NCI’s Center to Reduce Cancer Health Disparities has added new information about ways organizations can connect, and possibly partner, with its Screen to Save (S2S) program. In addition, more tools and resources have been added to the S2S page.

Video: Dr. Paul Jacobsen Talks About HDRP

In a new video, Paul Jacobsen, Ph.D., an associate director in the Division of Cancer Control and Population Sciences, discusses the Healthcare Delivery Research Program (HDRP) and how HDRP seeks to advance innovative cancer delivery research and better the delivery of cancer care.

2017 Cancer Close-Up Project

NCI’s 2017 Cancer Close Up project features cancer-related nanotechnology images. NCI-funded researchers were invited to submit their images for the annual project that shares visually compelling images that help to tell the cancer research story. The collection is available on NCI Visuals Online, and all images are free for anyone to download and use.

Spanish-Language Facebook Live

On March 29, NCI held its first ever Spanish-language Facebook Live Event , which addressed colorectal cancer screening and prevention.

Bringing Precision Screening to Breast Cancer

A new Research Update discusses how researchers are testing approaches that could identify those at greater risk of breast cancer who need to be screened and screening intervals that are appropriate for each person’s level of risk.

Aiming to Prevent Hereditary Cancers, Researchers Focus on Lynch Syndrome

Another new Research Update describes how experts at a workshop hosted by NCI discussed issues related to Lynch syndrome as a model for preventing hereditary cancers.

Understanding “Chemobrain” and Cognitive Impairment after Cancer Treatment

Researchers are investigating factors that might predict who’s at risk for experiencing “chemobrain” after cancer treatment and what can be done to lessen its impact, as this new Research Update reports.

Updated Head and Neck Cancer Fact Sheet

NCI’s fact sheet on head and neck cancers has been updated to include information about risk factors, statistics, and HPV vaccines.

Study Estimates Prevalence of Metastatic Breast Cancer

A new NCI-led study shows that the number of women in the United States living with distant metastatic breast cancer is growing, as this news release explains.

New Drug Information Summaries

New summaries on drugs used to treat cancer or its side effects have been added to NCI’s website, including summaries on:

Durvalumab (Imfinzi™), which was recently approved by the Food and Drug Administration (FDA) to treat urothelial carcinoma, which is a type of bladder cancer.
Avelumab (Bavencio®), which was recently approved to treat bladder cancer and Merkel cell carcinoma (MCC). This is the first drug approved by the FDA to treat MCC.
Niraparib (Zejula™), which was recently approved as maintenance therapy for some women with recurrent ovarian, fallopian tube, or primary peritoneal cancer.
Ribociclib (Kisqali®), which was recently approved to be used with other drugs to treat certain types of breast cancer. The FDA approval covers the use of ribociclib in postmenopausal women who have not been treated with hormone therapy.
Amifostine (Ethyol®) is approved to prevent toxic effects on the kidneys and dry mouth caused by certain cancer treatments.